Burden of antimicrobial resistance in an era of decreasing susceptibility

References

• World Health Day: Media Fact Sheet, Antimicrobial resistance: no action today, no cure tomorrow. Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gove/media
   Google Scholar
• Antibiotic Resistance: Multi-country Public Awareness Survey. World Health Organization; 2015. Available from: http://www.who.int/drugresistance/documents/baselinesurveynov2015/en/
   Google Scholar
• Antibiotic Resistance Threats in the United States 2013. Centers for Disease Control and Prevention; 2013. Available from: https://www.cdc.gov/drugresistance/threat-report-2013/index.html
   Google Scholar
• 2015 Summary report on antimicrobials sold or distributed for use in food-producing animals. FDA, Center for Veterinary Medicine; 2015. Available from: http://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm534244.htm
   Google Scholar
• Additives for use in animal nutrition. European Parliament and the Council of the European Union; 2003. Available from: http://data.europa.eu/eli/reg/2003/1831/oj
   Google Scholar
• Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem. 2014;6:25–64.
   PubMedGoogle Scholar
• Antimicrobial resistance: global report on surveillance 2014. World Health Organization; 2014 [cited 2014 Apr]. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/
   Google Scholar
• Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science (New York, NY). 2009;325:1089–1093. Epub 2009/08/29.
   Google Scholar
• Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance; 2014. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
   Google Scholar
• Taylor J, Hafner M, Yerushalmi E, et al. Estimating the economic costs of antimicrobial resistance: Model and Results. RAND Corporation; 2014.
   Google Scholar
• Selfin Y The global economic impact of antimicrobial resistance. KPMG UK; 2014. Available from: https://home.kpmg.com/content/dam/kpmg/pdf/2014/12/amr-report-final.pdf
   Google Scholar
• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–1301. Epub 2016/10/22.
   PubMed Web of Science ®Google Scholar
• Antimicrobial Surveillance in Europe 2014. European Centre for Disease Prevention and Control; 2014. Available from: http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf
   Google Scholar
• Micek S, Johnson MT, Reichley R, et al. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis. 2012;12:56. Epub 2012/03/15.
   PubMed Web of Science ®Google Scholar
• Hu B, Ye H, Xu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin. 2010;26:1443–1449.
   PubMed Web of Science ®Google Scholar
• Mauldin PD, Salgado CD, Hansen IS, et al. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54:109–115. Epub 2009/10/21.
   PubMed Web of Science ®Google Scholar
• Chandy SJ, Naik GS, Balaji V, et al. High cost burden and health consequences of antibiotic resistance: the price to pay. J Infect Dev Ctries. 2014;8:1096–1102.
   PubMed Web of Science ®Google Scholar
• Alam MF, Cohen D, Butler C, et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents. 2009;33:255–257. Epub 2008/12/19.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–4091.
   PubMed Web of Science ®Google Scholar
• Riu M, Chiarello P, Terradas R, et al. Cost attributable to nosocomial bacteremia. Analysis according to microorganism and antimicrobial sensitivity in a University Hospital in Barcelona. PLoS One. 2016;11:e0153076.
   PubMed Web of Science ®Google Scholar
• Tansarli GS, Karageorgopoulos DE, Kapaskelis A, et al. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013;11:321–331. Epub 2013/03/06.
   PubMed Web of Science ®Google Scholar
• Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago Teaching Hospital: implications for antibiotic stewardship. Clin Infect Dis Off Publ Infect Dis Soc America. 2009;49:1175–1184. Epub 2009/09/11.
   PubMed Web of Science ®Google Scholar
• Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2017;23:48.e9-.e16. Epub 2016/10/30.
   Google Scholar
• Lagace-Wiens PR, Adam HJ, Low DE, et al. Canadian Antimicrobial Resistance A. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother. 2013;68(Suppl 1):i23–9.
   PubMed Web of Science ®Google Scholar
• Pakyz AL, Lee JA, Ababneh MA, et al. Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitals. J Antimicrob Chemother. 2012;67:1562–1564.
   PubMed Web of Science ®Google Scholar
• Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22(Suppl 1):S9–S14.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem. 2008;15:517–522. Epub 2008/02/22.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li X, Li W, et al. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Sci Rep. 2015;5:11715.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Jun YH, Kim YR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC Infect Dis. 2014;14:161. Epub 2014/03/25.
   PubMed Web of Science ®Google Scholar
• Neidell MJ, Cohen B, Furuya Y, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis Off Publ Infect Dis Soc America. 2012;55:807–815. Epub 2012/06/16.
   PubMed Web of Science ®Google Scholar
• Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122. Epub 2012/05/25.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010;31:47–53.
   PubMed Web of Science ®Google Scholar
• Trends by Serotype Group. Centers for Disease Control and Prevention; 1998–2015. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html
   Google Scholar
• Ross JI, Eady EA, Cove JH, et al. 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998;42:1702–1705. Epub 1998/07/14.
   PubMed Web of Science ®Google Scholar
• Pneumonia Fact Sheet. World Health Organization; 2016. Available from: http://www.who.int/mediacentre/factsheets/fs331/en/
   Google Scholar
• Flamm RKRP, Huband MD, Farrell DJ. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program. ICAAC, C–554; 2014–2015. Available from: http://paratekpharma.com/media/1056/flamm2015icaacactivity-against-str-pneumoniae.pdf
   Google Scholar
• Keedy KLJ, Nenninger A, Sheets A, et al. Antibiotic susceptibility of Streptococcus pneumoniae in the USA in 2014. New Orleans: ID Week Conference 2016. 2016.
   Google Scholar
• Surveillance of invasive bacterial diseases in Europe 2012. European Center for Disease Prevention and Control; 2012. Available from: http://ecdc.europa.eu/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis Off Publ Infect Dis Soc America. 2007;44(Suppl 2): S27–72. Epub 2007/02/06.
   PubMed Web of Science ®Google Scholar
• Klepser ME, Klepser DG, Ernst EJ, et al. Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy. 2003;23:349–359. Epub 2003/03/12.
   PubMed Web of Science ®Google Scholar
• Einarsson S, Kristjansson M, Kristinsson KG, et al. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis. 1998;30:253–256. Epub 1998/10/28.
   PubMed Web of Science ®Google Scholar
• Asche C, McAdam-Marx C, Seal B, et al. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008;61:1162–1168.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Johnson MH, Kagan SA, et al. Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study. Infection. 2015;43:671–680.
   PubMed Web of Science ®Google Scholar
• Ostermann H, Garau J, Medina J, et al. Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm Med. 2014;14:36. Epub 2014/03/07.
   PubMed Web of Science ®Google Scholar
• Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia. Plos One. 2013;8:e71375.
   PubMed Web of Science ®Google Scholar
• Baldo V, Cocchio S, Baldovin T, et al. A population-based study on the impact of hospitalization for pneumonia in different age groups. BMC Infect Dis. 2014;14:485. Epub 2014/09/07.
   PubMed Web of Science ®Google Scholar
• Reynolds CA, Finkelstein JA, Ray GT, et al. Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: a cost analysis. Antimicrob Resist Infect Control. 2014;3:16. Epub 2014/05/23.
   PubMed Web of Science ®Google Scholar
• ABCs Report: Methicillin-resistant Staphylococcus aureus 2014. Centers for Disease Control and Prevention; 2014. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/mrsa14.html
   Google Scholar
• Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–318. Epub 2015/09/08.
   PubMed Web of Science ®Google Scholar
• Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents. 2006;28:379–384. Epub 2006/10/19.
   PubMed Web of Science ®Google Scholar
• Gould IM, Reilly J, Bunyan D, et al. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2010;16:1721–1728. Epub 2010/09/10.
   PubMed Web of Science ®Google Scholar
• Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20:973–980. Epub 2014/10/03.
   PubMed Web of Science ®Google Scholar
• Antonanzas F, Lozano C, Torres C. Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus. Pharmacoeconomics. 2015;33:285–325.
   PubMed Web of Science ®Google Scholar
• Rubio-Terres C, Garau J, Grau S, et al. Cast of Resistance Study g. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2010;16:722–728.
   PubMed Web of Science ®Google Scholar
• De Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8:e1001104. Epub 2011/10/25.
   PubMed Web of Science ®Google Scholar
• Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31:365–373.
   PubMed Web of Science ®Google Scholar
• Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. Aureus Bloodstream Infection? Infect Control Hosp Epidemiol. 2009;30:453–460.
   PubMed Web of Science ®Google Scholar
• Ott E, Bange FC, Reichardt C, et al. Costs of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2010;76:300–303.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48:3258–3262.
   PubMed Web of Science ®Google Scholar
• Taneja C, Haque N, Oster G, et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med. 2010;5:528–534.
   PubMed Web of Science ®Google Scholar
• Parvizi J, Pawasarat IM, Azzam KA, et al. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty. 2010;25:103–107.
   PubMed Web of Science ®Google Scholar
• Chen L, Todd R, Kiehlbauch J, et al. Notes from the field: pan-resistant New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae – Washoe County, Nevada, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:33. Epub 2017/01/13.
   PubMed Web of Science ®Google Scholar